Loading...
Market
Primary product type with boosted production at Sanofi by 2025
4
Resolution / Starting Odds
Vaccines • 50%
Biologic drugs • 50%
Sanofi production updates, industry news
Story
Sanofi Invests $1.08 Billion in French Biomanufacturing, Boosts EU Health Sovereignty
May 13, 2024, 06:45 AM
Sanofi announced plans to invest over 1 billion euros ($1.08 billion) to enhance its drug and vaccine production capabilities across three of its sites in France. This investment aims to expand biomanufacturing capacities and is part of a broader initiative to promote health sovereignty within the European Union.
View original story
Similar markets
COVID-19 vaccines • 33%
Influenza vaccines • 33%
Other vaccines • 34%
Oncology • 25%
Cardiovascular • 25%
Neurology • 25%
Immunology • 25%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Reduction by more than 20% • 33%
Reduction by 10% to 20% • 33%
Less than 10% reduction • 33%
Less than 500 jobs • 25%
500-999 jobs • 25%
1000-1499 jobs • 25%
1500 or more jobs • 25%
